AN2 Therapeutics (ANTX) Research & Development (2021 - 2026)
AN2 Therapeutics (ANTX) posted quarterly Research & Development of $6.7 million for Q1 2026, down 12.31% year-over-year from $7.7 million in Q1 2025, and down 1.98% quarter-over-quarter from $6.9 million in Q4 2025.
AN2 Therapeutics (ANTX) Research & Development (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has reported Research & Development for 6 consecutive years, with $6.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 12.31% year-over-year to $6.7 million; the TTM figure through Mar 2026 stood at $23.8 million (down 28.94% YoY), while the FY2025 annual figure was $24.8 million, down 38.82% from the prior year.
- Research & Development slipped to $6.7 million in Q1 2026 per ANTX's latest filing, from $6.9 million in the prior quarter.
- Across five years, Research & Development topped out at $14.9 million in Q4 2023 and bottomed at $3.2 million in Q2 2025.
- Historically, Research & Development has averaged $9.1 million across 5 years, with a median of $7.7 million in 2025.
- Annual changes were most pronounced in 2022 — Research & Development surged 241.6% — and 2025, when it plunged 73.66%.
- AN2 Therapeutics' Research & Development stood at $8.8 million in 2022, then surged by 70.46% to $14.9 million in 2023, then tumbled by 63.82% to $5.4 million in 2024, then rose by 27.46% to $6.9 million in 2025, then slipped by 1.98% to $6.7 million in 2026.
- Business Quant data shows ANTX's Research & Development at $6.7 million in Q1 2026, $6.9 million in Q4 2025, and $7.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | AN2 Therapeutics | 226.04 Mn | 226.04 Mn | - | 6.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.02 Mn |
| Mar 31, 2026 | 6.74 Mn |
| Dec 31, 2025 | 6.88 Mn |
| Sep 30, 2025 | 7.00 Mn |
| Jun 30, 2025 | 3.20 Mn |
| Mar 31, 2025 | 7.69 Mn |
| Dec 31, 2024 | 5.40 Mn |
| Sep 30, 2024 | 8.29 Mn |
| Jun 30, 2024 | 12.15 Mn |
| Mar 31, 2024 | 14.66 Mn |
| Dec 31, 2023 | 14.92 Mn |
| Sep 30, 2023 | 14.43 Mn |
| Jun 30, 2023 | 13.54 Mn |
| Mar 31, 2023 | 11.99 Mn |
| Dec 31, 2022 | 8.75 Mn |
| Sep 30, 2022 | 7.43 Mn |
| Jun 30, 2022 | 6.70 Mn |
| Mar 31, 2022 | 5.63 Mn |
| Dec 31, 2021 | 5.31 Mn |
| Sep 30, 2021 | 5.35 Mn |